BioCentury | Jul 10, 2019
Clinical News

Michael Becker, patient advocate and biotech exec, dies at 50

...publicly traded biotechnology companies, including cancer companies Cytogen Corp. (acquired by EUSA Pharma Inc.) and VioQuest Pharmaceuticals Inc....
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

...publicly traded biotechnology companies, including cancer companies Cytogen Corp. (acquired by EUSA Pharma Inc.) and VioQuest Pharmaceuticals Inc....
BioCentury | Nov 15, 2010
Finance

Spreading through China

...Infinity's first foray into biotech. Through an earlier fund it invested in two U.S. companies: Chiral Quest...
BioCentury | Mar 25, 2010
Distillery Therapeutics

Indication: Infectious disease

...of the Sutent plus Lenocta. Pfizer Inc. markets Sutent to treat renal and gastrointestinal cancers. VioQuest Pharmaceuticals Inc.'s...
BioCentury | Mar 4, 2010
Distillery Therapeutics

Indication: Cancer

...and is in Phase II testing to treat kidney, metastatic colon and several other cancers. VioQuest Pharmaceuticals Inc.'s...
BioCentury | Dec 8, 2008
Regulation

Vouching for Coartem

...one of the diseases on the FDAAA list. In its 10-Q filing in August 2008, VioQuest Pharmaceuticals Inc....
...to partner or license the priority review voucher that VioQuest expects to receive." In October, VioQuest...
...Medical Service of Washington , Washington, D.C. U.S. Food and Drug Administration (FDA), Rockville, Md. VioQuest Pharmaceuticals Inc....
BioCentury | Dec 8, 2008
Regulation

Tropical diseases pipeline

...NASDAQ:CRXL) Dukoral vaccine Prevent cholera Approved ex-U.S. Paladin Labs (TSX:PLB) Impavido miltefosine Leishmaniasis Approved ex-U.S. VioQuest...
BioCentury | Sep 15, 2008
Clinical News

Xyfid uracil regulatory update

...FDA notified VioQuest that its topical Xyfid 1% uracil to treat dermatoses would be regulated as...
...FDA alternative pathways for approval of Xyfid because an NDA submission would be "years away." VioQuest Pharmaceuticals Inc....
BioCentury | Aug 18, 2008
Company News

Arno management update

...OTCBB:ARNI), Fairfield, N.J. Business: Cancer Hired: Brian Lenz as CFO, formerly CFO and treasurer of VioQuest Pharmaceuticals Inc. WIR...
BioCentury | Jul 28, 2008
Company News

VioQuest management update

VioQuest Pharmaceuticals Inc. (OTCBB:VOQP), Basking Ridge, N.J. Business: Cancer, Chemistry, Supply/Service Hired: Christopher Schnittker as VP and CFO, formerly SVP and CFO at Micromet Inc. ; he replaces Brian Lenz, who resigned WIR Staff cancer...
Items per page:
1 - 10 of 55
BioCentury | Jul 10, 2019
Clinical News

Michael Becker, patient advocate and biotech exec, dies at 50

...publicly traded biotechnology companies, including cancer companies Cytogen Corp. (acquired by EUSA Pharma Inc.) and VioQuest Pharmaceuticals Inc....
BioCentury | Sep 7, 2017
Strategy

What if you build, but they don’t come

...publicly traded biotechnology companies, including cancer companies Cytogen Corp. (acquired by EUSA Pharma Inc.) and VioQuest Pharmaceuticals Inc....
BioCentury | Nov 15, 2010
Finance

Spreading through China

...Infinity's first foray into biotech. Through an earlier fund it invested in two U.S. companies: Chiral Quest...
BioCentury | Mar 25, 2010
Distillery Therapeutics

Indication: Infectious disease

...of the Sutent plus Lenocta. Pfizer Inc. markets Sutent to treat renal and gastrointestinal cancers. VioQuest Pharmaceuticals Inc.'s...
BioCentury | Mar 4, 2010
Distillery Therapeutics

Indication: Cancer

...and is in Phase II testing to treat kidney, metastatic colon and several other cancers. VioQuest Pharmaceuticals Inc.'s...
BioCentury | Dec 8, 2008
Regulation

Vouching for Coartem

...one of the diseases on the FDAAA list. In its 10-Q filing in August 2008, VioQuest Pharmaceuticals Inc....
...to partner or license the priority review voucher that VioQuest expects to receive." In October, VioQuest...
...Medical Service of Washington , Washington, D.C. U.S. Food and Drug Administration (FDA), Rockville, Md. VioQuest Pharmaceuticals Inc....
BioCentury | Dec 8, 2008
Regulation

Tropical diseases pipeline

...NASDAQ:CRXL) Dukoral vaccine Prevent cholera Approved ex-U.S. Paladin Labs (TSX:PLB) Impavido miltefosine Leishmaniasis Approved ex-U.S. VioQuest...
BioCentury | Sep 15, 2008
Clinical News

Xyfid uracil regulatory update

...FDA notified VioQuest that its topical Xyfid 1% uracil to treat dermatoses would be regulated as...
...FDA alternative pathways for approval of Xyfid because an NDA submission would be "years away." VioQuest Pharmaceuticals Inc....
BioCentury | Aug 18, 2008
Company News

Arno management update

...OTCBB:ARNI), Fairfield, N.J. Business: Cancer Hired: Brian Lenz as CFO, formerly CFO and treasurer of VioQuest Pharmaceuticals Inc. WIR...
BioCentury | Jul 28, 2008
Company News

VioQuest management update

VioQuest Pharmaceuticals Inc. (OTCBB:VOQP), Basking Ridge, N.J. Business: Cancer, Chemistry, Supply/Service Hired: Christopher Schnittker as VP and CFO, formerly SVP and CFO at Micromet Inc. ; he replaces Brian Lenz, who resigned WIR Staff cancer...
Items per page:
1 - 10 of 55